David Fawcett

Founder and CEO

Sabrina Hao

Partner

8 past transactions

Acorn Biolabs

Seed Round in 2019
Acorn Biolabs, Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. The company specializes in providing a take-home human cell cryopreservation service that focuses on non-invasive, follicle-based cell collection methods. Acorn Biolabs aims to preserve healthy young cells for potential future use in regenerative treatments, including gene therapies and stem cell therapeutics. Its services are accessible directly to consumers through both at-home and in-clinic collections, and the company partners with various clinics and pharmacies to expand its reach across Canada.

ThoughtWire

Series A in 2018
ThoughtWire is a developer of digital twin technology focused on enhancing the efficiency and safety of hospitals, commercial buildings, and cities. Its flagship platform, ThoughtWireOS, integrates data from people, processes, and the physical environment to create smarter spaces. By leveraging this data along with insights from Internet of Things (IoT) devices, ThoughtWire's applications offer real-time guidance and automation for various stakeholders, including clinicians, patients, office workers, and first responders. The company's software solutions aim to unlock the potential of built environments by ensuring energy efficiency, improving operational safety, and enabling proactive issue resolution. Through its innovative approach, ThoughtWire contributes to the development of self-optimizing systems that enhance the overall quality of life in urban settings and workplaces.

Muse

Series B in 2017
Muse, developed by InteraXon, is a neurotechnology company that produces a headband designed to provide real-time feedback on brain activity during meditation. Founded in 2007 and headquartered in Toronto, Ontario, the company specializes in brain-computer interfaces, utilizing research-grade ambulatory electroencephalograms and EEG sensors. Muse’s technology captures brainwaves and translates them into digital signals, which are then processed to deliver insights on mental activity, heart rate, breathing, and body movements. This data enables users to enhance their meditation practices and mindfulness, fostering a deeper connection with their mental and physical states. Through its innovative hardware and software platform, Muse aims to support users in achieving greater mental clarity and well-being.

Cyclica

Series A in 2017
Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform, which leverages artificial intelligence and biophysics. The company offers two main technologies: Ligand Design, which generates novel molecules and filters them based on various properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized protein repositories to assess poly-pharmacological profiles. This innovative approach allows pharmaceutical scientists to identify potential ligand-protein interactions, prioritize lead candidates, and explore opportunities for drug repurposing while also understanding potential adverse effects. Cyclica has established a strategic partnership with AUM Biosciences and has been operational since its incorporation in 2010.

Circle Cardiovascular Imaging

Venture Round in 2016
Circle Cardiovascular Imaging develops and markets cardiovascular post-processing software for the evaluation of magnetic resonance imaging (MRI) and CT images. It offers cmr42, a cardiovascular post-processing software for viewing and analyzing cardiovascular MR (CMR) images; ct42, a cardiovascular post-processing software for viewing and analyzing CCT images; cvi42, an integrated cardiovascular post-processing software for viewing and analyzing CMR and CCT images; and report42, a software solution that facilitates the documentation and reporting of CMR and CCT images. Circle Cardiovascular Imaging also provides product support, and training and education services for its software. Its software is used in the treatment of various indications, including heart failure, coronary artery disease, ischemic heart disease, myocardial infarction/scar, non-ischemic CM, myocarditis, valvular heart disease, cardiac masses, pericardial disease, pulmonary angiography, atrial fibrillation, carotid disease, and thoracic aortic disease. Its software is used by physicians and healthcare institutions in clinical and research settings. Circle Cardiovascular Imaging markets its software through a network of distributors worldwide. Kelly Cherniwchan founded it in 2007, with its headquarters in Calgary in Canada.

QoC Health

Seed Round in 2016
QoC Health Inc. is a Toronto-based company that specializes in developing a cloud-based digital platform aimed at enhancing patient engagement and improving healthcare outcomes. Founded in 2010, the company offers a range of solutions that facilitate patient monitoring, communication, and integration with existing medical records. Its flagship product, the Cloud Connect platform, enables healthcare providers to deploy tailored healthcare solutions for various scenarios, including post-discharge recovery monitoring, clinical research, and patient education. By connecting patients with healthcare providers, family, and peer support networks, QoC Health seeks to improve patient satisfaction, reduce readmissions, and lower overall healthcare costs. The platform is designed to simplify the implementation of compliant, connected technology solutions, thereby accelerating the delivery of advanced healthcare services across Canada.

Perimeter Medical Imaging

Series A in 2015
Perimeter Medical Imaging is a medical technology company focused on enhancing cancer surgery through innovative imaging solutions. The company specializes in ultra-high-resolution, real-time imaging tools designed to meet significant unmet medical needs in the surgical field. By providing advanced imaging capabilities, Perimeter aims to improve the accuracy and outcomes of cancer surgeries, ultimately benefiting patients and healthcare providers alike.

ChipCare

Series A in 2015
ChipCare’s mission is to bring lab-based medical tests to patients, enabling every person around the world to have easy access to state-of-the-art blood tests. The envisioned product entails two components: handheld reader and disposable test slide. The revenue will mainly be generated from sales of disposable test slides (consumables). Our proprietary detection technique enables testing of multiple diseases from a single drop of blood sample, including cell counting, protein/enzyme and pathogen detection. ChipCare’s solution to this problem is an integrated point-of-care testing and monitoring system to address the current clinical challenges in both resource rich and resource limited settings. It combines patient identification, blood testing, communication, and external quality management protocol. It is also a platform system that can be used to test different diseases from a single drop of blood.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.